Stock Research for cnbx

cnbx

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

cnbx Stock Chart & Research Data

The cnbx chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the cnbx chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


cnbx Due diligence Resources & Stock Charts

The cnbx stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View cnbx Detailed Price Forecast - CNN Money CNN View cnbx Detailed Summary - Google Finance
Yahoo View cnbx Detailed Summary - Yahoo! Finance Zacks View cnbx Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View cnbx Trends & Analysis - Trade-Ideas Barrons View cnbx Major Holders - Barrons
NASDAQ View cnbx Call Transcripts - NASDAQ Seeking View cnbx Breaking News & Analysis - Seeking Alpha
Spotlight View cnbx Annual Report - CompanySpotlight.com OTC Report View cnbx OTC Short Report - OTCShortReport.com
TradeKing View cnbx Fundamentals - TradeKing Charts View cnbx SEC Filings - Bar Chart
WSJ View Historical Prices for cnbx - The WSJ Morningstar View Performance/Total Return for cnbx - Morningstar
MarketWatch View the Analyst Estimates for cnbx - MarketWatch CNBC View the Earnings History for cnbx - CNBC
StockMarketWatch View the cnbx Earnings - StockMarketWatch MacroAxis View cnbx Buy or Sell Recommendations - MacroAxis
Bullish View the cnbx Bullish Patterns - American Bulls Short Pains View cnbx Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View cnbx Stock Mentions - StockTwits PennyStocks View cnbx Stock Mentions - PennyStockTweets
Twitter View cnbx Stock Mentions - Twitter Invest Hub View cnbx Investment Forum News - Investor Hub
Yahoo View cnbx Stock Mentions - Yahoo! Message Board Seeking Alpha View cnbx Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for cnbx - SECform4.com Insider Cow View Insider Transactions for cnbx - Insider Cow
CNBC View cnbx Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for cnbx - OTC Markets
Yahoo View Insider Transactions for cnbx - Yahoo! Finance NASDAQ View Institutional Holdings for cnbx - NASDAQ


Stock Charts

FinViz View cnbx Stock Insight & Charts - FinViz.com StockCharts View cnbx Investment Charts - StockCharts.com
BarChart View cnbx Stock Overview & Charts - BarChart Trading View View cnbx User Generated Charts - Trading View




Latest Financial News for cnbx


Cannabics Pharmaceuticals and Wize Pharma to Form Joint Venture to Develop Cannabinoid Based Ophthalmic Therapeutics
Posted on Thursday February 07, 2019

BETHESDA, Maryland and TEL AVIV, Israel, Feb. 7, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has entered into agreement with Wize Pharma, Inc. (WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases. Initially announced in a press release on June 29, 2018, the two companies have been advancing planning and have concluded, that subject to completing a mutually agreeable business plan and obtaining an expert opinion in order to identify a potential FDA route for ophthalmic therapy containing cannabinoids, each expected to occur within 30 days, that they are ready to form a joint venture (JV) company, for the purpose of researching, developing, and administering cannabinoid formulations to treat ophthalmic disorder indications.


Wize Pharma, Inc. Signs Joint Venture With Cannabics, to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions
Posted on Thursday February 07, 2019

HOD HASHARON, Israel, Feb. 7, 2019 /PRNewswire/ -- Wize Pharma, Inc. ("Wize Pharma" or the "Company") (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company has signed an agreement to form a joint venture (JV) company for the purpose of researching, developing and administering cannabinoid formulations to treat ophthalmic conditions  with Cannabics Pharmaceuticals Inc. ("Cannabics") (OTCQB: CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects. The agreement will become effective subject to receipt of an expert opinion, within 30 days from the date of signing, describing the regulatory pathway for eye drops containing cannabinoids.  Upon effectiveness, Wize shall issue 900,000 shares of its common stock to Cannabics and Cannabics shall issue 2,263,944 shares of its common stock to Wize.  The agreement shall expire if the parties have not approved a business plan by June 30, 2019.


Cannabics Pharmaceuticals Files Four New Provisional Patent Applications for Cannabinoid-Based Drugs and Treatments for Non-Epileptic Seizures and Tremors
Posted on Thursday January 31, 2019

TEL AVIV, Israel and BETHESDA, Maryland, Jan. 31, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced that it has filed an additional four provisional patent applications with the Israel Patent Office, for cannabinoid-based drugs and treatments, designed for conditions associated with non-epileptic seizures and tremors. Dr. Eyal Ballan and Eyal Barad, co-founders of Cannabics, believe that the company's clinical experience and personalization platform may allow for personalized cannabinoid solutions for conditions and syndromes such as Alcohol Withdrawal Syndrome (AWS), REM related sleep disorder (RBD), Psychogenic non-epileptic seizures (PNES) and Drug-induced tremors, found as extrapyramidal side effects (EPSE).


Cannabics Pharmaceuticals and NewCanna Hub Intend to Collaborate to Manufacture and Market Cannabics' SR Capsules in Colombia
Posted on Thursday January 24, 2019

TEL AVIV, Israel and BETHESDA, Maryland, Jan. 24, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects announced, that NewCanna Hub, a world leader in the field  of cannabinoids, have signed a non-binding letter of intent ("LOI") today at The World Economic Forum, in Davos, Switzerland, to establish an equal joint venture that is intended to produce and market Cannabics' Slow Release ("SR") capsules in Colombia and, potentially, other regulated markets. Pursuant to the terms of the LOI, the parties intend to develop a joint business plan for the joint venture within the next 30 days and execute a definitive joint venture agreement as soon as reasonably practicable. As part of the new proposed joint venture, the SR capsules are expected to be produced at NewCanna's Good Manufacturing Practice (GMP) certified facility in Columbia in various formulations.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.